Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Income towards Parent Company: 2021-2024

Historic Income towards Parent Company for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Income towards Parent Company fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.0 million for FY2024, which is 114.71% up from last year.
  • ARS Pharmaceuticals' Income towards Parent Company amounted to $8.0 million in FY2024, which was up 114.71% from -$54.4 million recorded in FY2023.
  • In the past 5 years, ARS Pharmaceuticals' Income towards Parent Company ranged from a high of $8.0 million in FY2024 and a low of -$54.4 million during FY2023.
  • For the 3-year period, ARS Pharmaceuticals' Income towards Parent Company averaged around -$27.3 million, with its median value being -$35.5 million (2022).
  • As far as peak fluctuations go, ARS Pharmaceuticals' Income towards Parent Company slumped by 82.56% in 2022, and later spiked by 114.71% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Income towards Parent Company (Yearly) stood at -$19.5 million in 2021, then crashed by 82.56% to -$35.5 million in 2022, then plummeted by 53.07% to -$54.4 million in 2023, then spiked by 114.71% to $8.0 million in 2024.